iBio Names New Director Following Board Departure

iBio Inc. (NYSE American: IBIO) disclosed the departure of one director and the election of another in a Form 8-K filed with the SEC on May 8, 2026.

The filing covers Item 5.02 on departure or election of directors or principal officers, Item 7.01 on Regulation FD disclosure, and Item 9.01 on financial statements and exhibits. iBio, a biotechnology company focused on protein expression technologies, now operates with an updated board that includes the newly elected member while one prior director has left.

The operational delta consists of a board seat transition. One unnamed director departed the board, and a new individual was elected to fill a vacancy. The filing does not specify an effective date beyond the May 8 disclosure itself or cite a cause for the departure. Public companies must report such board-level changes on Form 8-K within four business days under SEC rules.

Downstream consequences include updated governance documentation that iBio must maintain for future proxy statements and potential NYSE American compliance filings. The board composition shift requires the company to reflect the change in its next definitive proxy statement under SEC Schedule 14A rules.

Markets and investors gain immediate notice through the 8-K, which also contains any Regulation FD information released concurrently to avoid selective disclosure violations. No principal officer changes occurred, so executive leadership continuity remains intact.

This marks the latest board adjustment for iBio, a non-watchlist issuer with CIK 0001420720 that has used the 8-K format to report director and officer matters in prior years. The filing constitutes the official record and contains no additional financial exhibits beyond those required for Item 9.01 compliance.

The complete 8-K is available on the SEC EDGAR system under accession number 0001104659-26-057945.